Aug.23.2024
R & D
Bristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma
This material is intended to notify the press release issued on August 21 (local time) by Bristol Myers Squibb, our license partner for Opdivo.
Please click https://www.bms.com/media/press-releases.html for the original press release.